5/8/2025

Amgen is an innovative leader in an industry where its products will always be in high demand. Microsoft is navigating the current situation well and boasts lucrative growth opportunities. Two excellent options right now are Amgen (NASDAQ: AMGN) and Microsoft (NASDAQ: MSFT).

Source: Yahoo

5/8/2025

BeiGene's innovative cancer treatments, Brukinsa and Tevimbra, are driving growth. Click for a look at ONC and its latest earnings results.

Source: SeekingAlpha

5/7/2025

We came across a bullish thesis on Amgen Inc. (AMGN) on Substack by Magnus Ofstad. In this article, we will summarize the bulls’ thesis on AMGN. Amgen Inc. (AMGN)’s share was trading at $281.22 as of May 2nd. AMGN’s trailing and forward P/E were 25.64 and 13.48 respectively according to Yahoo Finance. Amgen (AMGN) delivered a strong […]

Source: Yahoo

5/7/2025

We recently published a list of The Best and Worst Dow Stocks. In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against other Dow stocks. The Dow Jones Industrial Average is a benchmark index of the top 30 companies in the US. It represents the strength of the […]

Source: Yahoo

5/7/2025

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Source: Yahoo

5/6/2025

Merck, Amgen share losses lead Dow's nearly 275-point drop

Source: MarketWatch

5/6/2025

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Source: Yahoo

5/6/2025

Merck, Amgen share losses contribute to Dow's 375-point drop

Source: MarketWatch

5/6/2025

Merck, Amgen share losses contribute to Dow's 238-point drop

Source: MarketWatch

5/6/2025

Merck, Amgen share losses contribute to Dow's 133-point fall

Source: MarketWatch

5/6/2025

Dow's 300-point drop led by losses in shares of Merck, NVIDIA Corp.

Source: MarketWatch

5/6/2025

Amgen's diverse portfolio ensures stability, but risks like high debt and biosimilar competition loom. Check out my look at AMGN stock after its Q1 earnings.

Source: SeekingAlpha

5/5/2025

Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.

Source: Yahoo

5/5/2025

AMGN's 14 products, including Repatha, Blincyto, Tezspire, Tavneos and Evenity, achieve double-digit volume growth in the first quarter.

Source: Yahoo

5/5/2025

Dow's 175-point drop led by losses for shares of Chevron, Apple

Source: MarketWatch

5/4/2025

Amgen's fundamentals stay strong with rising EPS, dividend yield, and new drug momentum, despite technical pullbacks. See why AMGN stock is a buy.

Source: SeekingAlpha

5/3/2025

Discover the top Dow Dogs for potential gains of 21%-45% by 2026, with Verizon leading in dividends. Read more on the price gainers for 2026 based on 1-year target prices.

Source: SeekingAlpha

5/2/2025

Amgen (NasdaqGS:AMGN) recently reported strong financial results for Q1 2025, showing a turnaround from a loss to a substantial net income. This positive performance included ambitious revenue and earnings guidance for the year, likely adding weight to the broader market's upward trend, as reflected in a 1.41% price increase. The expansion of the company's manufacturing capabilities and stable share buyback updates may have further supported investor confidence. During this time, broader...

Source: Yahoo

5/2/2025

Sales of the company’s copycat to J&J’s blockbuster medicine reached $150 million in the first quarter, adding to a surge in revenue for Amgen's biosimilar business.

Source: Yahoo

5/2/2025

Q1 2025 Amgen Inc Earnings Call

Source: Yahoo